Visit from Charles Sabine, OBE

Last week at the Babraham Research Campus, we were privileged to hear Charles Sabine, OBE, speak about living with Huntington's disease (HD) and his tireless mission to transform how the condition is understood and addressed.

Charles shared how seeing the impact of HD within his own family led him to use his voice and network to bring long-overdue attention to a disease that was historically under-recognised and underfunded.

His message was one of cautious optimism. Thanks to years of work by patients and researchers, the HD landscape has fundamentally shifted, with multiple therapeutic approaches now advancing in the clinic. He believes the next 5-10 years could deliver the first approved therapies with the potential to change the course of the disease.

This is exactly what inspires our work at Harness Therapeutics, as we focus on approaches that aim to address the underlying drivers of neurodegenerative disease.

Thank you to Charles for his honesty, insight, and relentless advocacy for the HD community, and to LoQus23 Therapeutics Ltd, Alchemab Therapeutics Ltd, and TRIMTECH Therapeutics Limited for joining us in hosting this important event.

hashtag#HarnessTherapeutics hashtag#Biotech hashtag#HuntingtonsDisease hashtag#PatientFocus